Our Company
About Us
About Xanamem
®
Our Team
Recent Annual Reports
Our Strategic Priorities
Corporate Governance
Xanamem
®
The Cortisol Hypothesis
Mechanism of Action
Publications
Clinical Trials
Clinical Development Pipeline
Cognitive Impairment in early Alzheimer’s Disease
Cognitive Impairment in MDD
Anxiety, sleep & behavioral problems in Fragile X Syndrome
Patient Portal
Participate in clinical trials
The XanaMIA Phase 2b/3 Alzheimer’s Trial
Publications
Investor Centre
Share Price
ASX Announcements
Press Releases
Corporate Presentations
Analyst Reports
Financial Results Centre
Annual General Meeting
General Meeting
Financial Calendar
Target Market Determination
Right to Receive Documents
Frequently Asked Questions
Investor Contacts
News
Contact Us
Submit Your Details
To access the PDF, please complete the details below.
Back
to top
